Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for Refractory Cerebral Vasospasm after aSAH
NCT04988932Completed
- Sponsor
- Insel Gruppe
- Start
- Jul 2012
- Primary completion
- Jul 2019
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Open-label, single-arm trial of nitric oxide in cerebral vasospasm, sponsored by Insel Gruppe. Primary endpoints: Improvement of severe vasospasm in digital subtraction angiography up to 5 days, Improvement of severe vasospasm in tissue oxygen partial pressure (PtiO2) up to 5 days and 2 more. Started Jul 2012; status: completed.
02
Drugs
nitric oxide
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on NCT04988932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988932.